ABOS
NASDAQAcumen Pharmaceuticals Inc.
Price$2.37-0.03 (-1.46%)
01:30 PM07:45 PM
News · 26 weeks63+43%
2025-12-142026-06-07
Mix3190d
- SEC Filings12(39%)
- Insider10(32%)
- Other5(16%)
- Earnings4(13%)
Latest news
25 items- INSIDERDirector Fountain Nathan B sold $14,273 worth of shares (6,400 units at $2.23), decreasing direct ownership by 12% to 48,150 units (SEC Form 4)4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)
- INSIDERDirector Ra Capital Management, L.P. was granted 35,500 shares (SEC Form 4)4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)
- INSIDERDirector Fountain Nathan B was granted 35,500 shares, increasing direct ownership by 186% to 54,550 units (SEC Form 4)4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)
- INSIDERDirector Drapkin Kimberlee C was granted 35,500 shares, increasing direct ownership by 277% to 48,300 units (SEC Form 4)4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)
- INSIDERDirector Stalfort John A Iii was granted 35,500 shares, increasing direct ownership by 19% to 220,624 units (SEC Form 4)4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)
- INSIDERDirector Porter Derrell was granted 35,500 shares, increasing direct ownership by 277% to 48,300 units (SEC Form 4)4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)
- INSIDERDirector Ives Jeffrey L. was granted 35,500 shares, increasing direct ownership by 277% to 48,300 units (SEC Form 4)4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)
- INSIDERDirector Golumbeski George was granted 35,500 shares (SEC Form 4)4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)
- INSIDERDirector Stoppel Laura was granted 35,500 shares (SEC Form 4)4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)
- SECAcumen Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
- SECSEC Form 10-Q filed by Acumen Pharmaceuticals Inc.10-Q - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
- SECAcumen Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
- PRAcumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business HighlightsExpect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in late 2026Lead clinical candidate IND filing in Acumen's EBDTM (enhanced brain delivery) program targeted for mid-2027Cash, cash equivalents and marketable securities of $128.4 million as of Mar. 31, 2026, expected to support current clinical and operational activities into early 2027 Company to host conference call and webcast today at 8:00 a.m. ET NEWTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutic
- PRAcumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care ConferenceNEWTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the Bank of America Securities 2026 Health Care Conference on Thursday, May 14, 2026, at 8:55 a.m. PT/11:55 a.m. ET. The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days. About Acumen Pharmaceuticals, Inc. Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics tha
- PRAcumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026NEWTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report first quarter financial results on Tuesday, May 12, 2026. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update. To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one
- SECSEC Form DEFA14A filed by Acumen Pharmaceuticals Inc.DEFA14A - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
- SECSEC Form DEF 14A filed by Acumen Pharmaceuticals Inc.DEF 14A - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
- SECSEC Form SCHEDULE 13G filed by Acumen Pharmaceuticals Inc.SCHEDULE 13G - Acumen Pharmaceuticals, Inc. (0001576885) (Subject)
- SECSEC Form EFFECT filed by Acumen Pharmaceuticals Inc.EFFECT - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
- SECSEC Form 424B3 filed by Acumen Pharmaceuticals Inc.424B3 - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
- SECSEC Form S-3 filed by Acumen Pharmaceuticals Inc.S-3 - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
- SECSEC Form S-8 filed by Acumen Pharmaceuticals Inc.S-8 - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
- SECSEC Form 10-K filed by Acumen Pharmaceuticals Inc.10-K - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
- SECAcumen Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
- PRAcumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business HighlightsExpect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in late 2026Lead clinical candidate IND filing in Acumen's Enhanced Brain Delivery (EBDTM) program targeted for mid-2027, following strong preclinical data and $35.75 million private placement to advance candidates in AβO-selective EBD portfolioCash, cash equivalents and marketable securities of $116.9 million as of Dec. 31, 2025, expected to support current clinical and operational activities into early 2027 Company to host conference call and webcast today at 8:00 a.m. ET NEWTON, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceut
ABOS FAQ
7 questionsWhat does Acumen Pharmaceuticals Inc. do?
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapeutics for the treatment of Alzheimer's and other neurodegenerative diseases. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, which is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is based in Charlottesville, Virginia.Where does ABOS stock trade?
Acumen Pharmaceuticals Inc. (ABOS) is listed on NASDAQ.What sector and industry is ABOS in?
Acumen Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Acumen Pharmaceuticals Inc. go public?
Acumen Pharmaceuticals Inc. (ABOS) completed its IPO in 2021.What are analysts saying about ABOS?
Acumen Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Citigroup: Buy with a $400.00 price target on 2025-06-17. Recent price targets range from $400.00 to $1500.00.What companies are similar to ABOS?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare ABOS side-by-side with any of them on Quantisnow.How can I track ABOS on Quantisnow?
Quantisnow aggregates Acumen Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ABOS to receive live email and push alerts on every new disclosure.